<DOC>
	<DOCNO>NCT00853658</DOCNO>
	<brief_summary>The study evaluate efficacy safety aliskiren monotherapy aliskiren/enalapril combination therapy compare enalapril monotherapy , morbidity mortality patient chronic heart failure ( NYHA Class II - IV .</brief_summary>
	<brief_title>Efficacy Safety Aliskiren Aliskiren/Enalapril Combination Morbidity-mortality Patients With Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Inclusion Criteria Patients eligible inclusion study fulfill follow criterion : 1 . Patients ≥ 18 year age , male female . 2 . Patients diagnosis chronic heart failure ( NYHA Class II IV ) : 1 . LVEF ≤ 35 % Visit 1 ( local measurement , within past 6 month assess echocardiography , multiple uptake gated acquisition scan ( MUGA ) , computerize tomography ( CT ) scan , magnetic resonance imaging ( MRI ) ventricular angiography ) 2 . Elevated BNP NTproBNP Visit 1 : BNP ≥ 150 pg/mL ( BNP ≥ 100 pg/mL unplanned hospitalization HF within last 12 month prior Visit 1 ) ( accord local measurement ) . OR NTproBNP ≥ 600 pg/mL ( NTproBNP ≥ 400 pg/mL unplanned hospitalization HF within last 12 month prior Visit 1 ) ( accord local measurement ) . 3 . Patients treat ACEI stable dose enalapril 10 mg daily least ACEI , e.g . ramipril , quinapril , lisinopril , fosinopril , perindopril , trandolapril ; base equivalent dos , least 4 week prior Visit 1 4 . Patients treated betablocker , unless contraindicate tolerated , stable dose least 4 week prior visit 1 ( patient target dose , accord local guideline , absence medication , reason document ) . 5 . Written inform consent participate study ability comply requirement . Exclusion Criteria Patients follow exclude participation study : 1 . History hypersensitivity study drug include history allergy ACEIs well known suspect contraindication study drug previous history intolerance high dos ACEIs titration process . 2 . Patients treat concomitantly ARB aldosterone antagonist addition study drug Visit 1 . 3 . Current acute decompensated HF ( define acute exacerbation chronic heart failure status manifest typical sign symptom HF like dyspnea , fatigue etc. , may require IV therapy diuretic , vasodilator and/or inotropic drug ) . 4 . Symptomatic hypotension and/or le 95 mmHg systolic blood pressure ( SBP ) Visit 1 and/or less 90 mmHg SBP Visit 4 . 5 . Acute coronary syndrome , stroke , transient ischemic attack , cardiac , carotid major vascular surgery , percutaneous coronary intervention ( PCI ) carotid angioplasty , within past 3 month prior Visit 1 . 6 . Coronary carotid artery disease likely require surgical percutaneous intervention within 6 month Visit 1 . 7 . Right heart failure due severe pulmonary disease . 8 . Patients Diabetes Mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Cardiovascular death</keyword>
	<keyword>CHF hospitalization</keyword>
	<keyword>morbi-mortality trial</keyword>
	<keyword>outcome study</keyword>
	<keyword>endpoint driven</keyword>
	<keyword>plasma renin activity</keyword>
	<keyword>renin angiotensin aldosterone system</keyword>
	<keyword>direct renin inhibitor</keyword>
	<keyword>BNP</keyword>
	<keyword>KCCQ</keyword>
	<keyword>eGFR</keyword>
	<keyword>( NYHA class II IV ) elevate</keyword>
	<keyword>BNP reduce LVEF</keyword>
</DOC>